Agents that neutralize VEGF-A or inhibit VEGF receptor tyrosine kinase activity have been extensively evaluated in clinical trials of ovarian cancer patients and a limitation of these agents is acquired resistance [36]. The gene discussed is VEGFA; the disease is ovarian cancer.